Wednesday, July 8, 2026

Patent intelligence · US

US 6723695

CTL epitopes from EBV

expired A61KA61K39/00A61K40/11A61K40/46
Status expired
Linked drugs 3
Pipeline programs 6
Years to expiry 0
Applicant portfolio 1
Patent details — US 6723695

Quick answer

US 6723695 (CTL epitopes from EBV) is held by Commonwealth Scientific and Industrial Research Organisation of Limestone Avenue. Status: expired. Granted Apr 20, 2004. Expires Apr 15, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61K, A61K39/00, A61K40/11, A61K40/46, A61P, A61P31/12

Frequently asked questions

What is US patent 6723695?

US 6723695 (CTL epitopes from EBV) is held by Commonwealth Scientific and Industrial Research Organisation of Limestone Avenue. Status: expired. Granted Apr 20, 2004. Expires Apr 15, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6723695?

Commonwealth Scientific and Industrial Research Organisation of Limestone Avenue is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.

When does US 6723695 expire?

Our index shows an expiration date of Apr 15, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.